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Outcome measurement and reporting in childhood
epilepsy treated with ketogenic diet therapy: a scoping
review protocol
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Review question: The objective of this scoping review is to investigate the outcomes measured and reported in
trials of children with refractory epilepsy treated with ketogenic diet therapy. The scoping review will aim to list the
outcomes and map the associated components including intervention (type of ketogenic diet therapy), definition
(if used) of the outcome, the tool or indicators used to measure the outcome, validity of tool used, the time from
intervention commencement to measurement of the outcome and the reporting of the outcome.
Specifically, the review question is: Which outcomes are measured and reported in studies of childhood epilepsy
treated with ketogenic diet therapy?
Keywords Childhood; core outcome set; epilepsy; ketogenic diet; outcomes
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Introduction
E pilepsy is a condition where individuals areprone to recurrent epileptic seizures. This may
result from a number of different causes, although
initial treatment remains antiepileptic medications.
Although two-thirds of people will respond or enter
spontaneous remission, up to one-third of children
with epilepsy will be refractory to standard anti-
epileptic medication.1 The International League
Against Epilepsy (ILAE) describe refractory epilepsy
as failure to achieve sustained seizure freedom with
two appropriate and tolerated anti-epileptic drugs.2
When resective epilepsy surgery is not feasible, other
non-pharmacological treatments including keto-
genic diet (KD) therapy are considered.3 The KD
is a high-fat, restricted-carbohydrate regimen that
has been used as a treatment for refractory epilepsy
since its first reported use in 1921.4 There are many
types of KD in use with varying degrees of dietary
restriction. The classical KD is based on a ratio of fat
to carbohydrate, usually 3:1 or 4:1.5 Long-chain
triglycerides are the predominant fat source, carbo-
hydrate is heavily restricted and protein is limited to
that required for growth. The medium chain triglyc-
eride (MCT) KD6 allows a slightly higher carbohy-
drate and protein intake than classical KD, as
medium-chain triglyceride fat is absorbed and trans-
ported more efficiently than long-chain triglyceride
fat, with greater ketone production per unit of die-
tary energy.7 In addition to the traditional KD,
modified versions are often used and include the
modified Atkins diet,8 modified KD used in the
United Kingdom with similar principles to modified
Atkins diet and the low glycemic index treatment.9
These modified versions take a less restrictive
approach than the more traditional classical and
MCT KDs, but the principles of high-fat and low-
carbohydrate intake remain and require significant
dietary adjustment for the child.
Ketogenic diet therapy is a well-established treat-
ment for refractory epilepsy, with more than 50% of
children achieving greater than 50% seizure reduc-
tion in retrospective and prospective observational
studies.10-13 Three key randomized controlled trials
(RCTs) assessing the efficacy of KD have been pub-
lished: Neal et al.5 using the classical and MCT KD,
Sharma et al.14 using the modified Atkins diet and
Lambrechts et al.15 theMCTKD. In all three studies,
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significantly more children treated with KD therapy
experienced seizure reduction of at least 50% than
those in the usual care control group; (38% versus
6%),5 (52% versus 11.5%)14 and (50% versus
18%).15 Neal et al.5 demonstrated that the classical
and MCT KD were comparable in efficacy and
tolerability.
Typically, seizure reduction or seizure freedom
are the primary outcomes of choice with attrition,
tolerability and adverse effects often considered sec-
ondary outcomes. A more holistic approach might
also consider health-related quality-of-life out-
comes, such as reduced hospitalization,16 reduced
medication load and cost,17 and improved behavior
and cognition.18 A recent Cochrane review19 found
only one RCT assessing the effect of KD on quality of
life, cognition and behavior. They suggest future
studies should use validated tools to assess these
outcomes. Standardized and validated tools such
as the PedsQL,20 Child Health Questionnaire
(CHQ)21 and the epilepsy specific Quality of Life
in Childhood Epilepsy (QOLCE)22 questionnaire
aim to assess the impact of chronic disease on child-
hood quality of life. However, shortcomings and
challenges exist when applying these tools to
populations with disability. In clinical practice,
ketogenic teams try to address these shortcomings
by developing alternative questionnaires tailored
for parents or caregivers of children with chronic
epilepsy.23
There is no general consensus on which outcomes
should be reported in clinical trials for most clinical
areas, including childhood epilepsy treated with
KD therapy. Reaching consensus on a core set of
outcomes would reduce outcome reporting bias,
improve quality and relevance of research, improve
reporting consistency and support meta-analysis
leading to better informed healthcare decisions.24
The authors have chosen to conduct a scoping review
to provide a descriptive overview of the outcomes
currently measured and reported in childhood epi-
lepsy. Prior to developing the present review proto-
col, preliminary searches were undertaken to
identify any existing scoping or systematic reviews
published or underway on a similar or identical topic.
The JBI Database of Systematic Reviews and Imple-
mentationReports, PROSPERO,CochraneDatabase
of Systematic Reviews, CINAHL and PubMed were
searched andno relevant reviewswere identified.This
proposed scoping review will follow the approach
recommended by the Joanna Briggs Institute
(JBI).25,26 The scoping review methodology was cho-
sen for its suitability for addressing the proposed
aim—namely, to identify a comprehensive list of out-
comes measured and reported in childhood epilepsy
treated with KD therapy. Furthermore, this review
will explore the definitions of outcomes, the tools or
methods employed to measure the outcome, the time
from KD therapy commencement to measurement of
the outcome and the reporting of the outcomes.
Collating and mapping this information will inform
the process of developing a core outcome set for use
in clinical practice and future research trials, using
methodology recommended by the Core Outcome
Measures in Effective Trials (COMET) Initiative.24
Inclusion criteria
Participants
The scoping review will consider studies that include
male and female children 18 years or younger with
epilepsy treated with KD therapy for at least one
month. Studies undertaken with adults will be
excluded. Children treated with KD therapy for a
diagnosis other than childhood epilepsy will be
excluded (e.g. neuro-oncology and metabolic disor-
ders).
Concept
This review will consider the outcomes measured
and reported in studies that assess the use of KD
therapy to treat childhood epilepsy. The following
components will be investigated: intervention (type
of KD therapy), outcomes, definition (if used) of the
outcome, the tool or indicators used to measure the
outcome, validity of tool used, the time from KD
therapy commencement to measurement of the out-
come and the reporting of the outcome. Participants
may be treated with other medical therapies includ-
ing, but not limited to, anti-epileptic medications or
surgery in conjunction with KD therapy.
Context
The context of this review will be settings with
pediatric patients undertaking KD therapy for
refractory epilepsy.
Types of studies
This scoping review will consider both experimental
and quasi-experimental study designs including
RCTs, non-randomized controlled trials, before
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and after studies and interrupted time-series studies.
There are only seven RCTs19 examining KD therapy,
so analytical observational studies including pro-
spective and retrospective cohort studies, case-
control studies and analytical cross-sectional studies
will be considered for inclusion. The first RCT
assessing the effectiveness of KD for childhood epi-
lepsy5 and the first internationally agreed guidelines
on the management of children treated with KD
therapy were published in 2008.3 These two key
publications have guided subsequent research and
the clinical management of children treated with
KD. Therefore, studies published from 2008
onwards will be included. Inclusion of a variety of
study designs will ensure a large number of relevant
studies will be reviewed, and repetition of measured
and reported outcomes is expected. Studies pub-
lished in English will be included. Systematic reviews
will be excluded at the title and abstract screening
phase. However, the reference lists will be reviewed
to ensure all primary studies have been identified in
the searches. The reference list of all studies selected
for inclusion will be screened for additional studies.
Methods
The proposed systematic review will be conducted in
accordance with the Joanna Briggs Institute meth-
odology for scoping reviews.25
Search strategy
The search strategy will aim to find both published
and unpublished studies. An initial limited search of
PubMed and CINAHL was undertaken, followed by
analysis of the text words contained in the title and
abstract, and of the index terms used to describe
articles. This informed the development of a search
strategy tailored for each information source. A full
search strategy for PubMed is detailed in Appendix I.
Information sources
The databases to be searched will include Cochrane
Database of Systematic Reviews, Cochrane CEN-
TRAL, CINAHL, PubMed, Scopus, Embase, AMED
and JBI Database of Systematic Reviews and Imple-
mentation Reports. The trial registers to be searched
will include ISRCTN registry and ClinicalTrials.gov.
The search for unpublished studies will include the
British Library e-theses online services (EThOS)
database, OAIster and OpenGrey (System for Infor-
mation on Grey Literature in Europe; SIGLE). An
expert in the field will be consulted to ensure no
studies are missed.
Study selection
Following the search, all identified citations will be
collated and uploaded into EndNote V8 (Clarivate
Analytics, PA, USA) and duplicates removed. Titles
and abstracts will then be screened by two indepen-
dent reviewers for assessment against the inclusion
criteria for the review. The reference list of system-
atic reviews will be reviewed to ensure all primary
studies have been identified in the searches. The
reference list of all studies selected for inclusion will
be screened for additional studies.
Studies that meet the inclusion criteria will be
retrieved in full and their details imported into the
JBI System for the Unified Management, Assessment
and Review of Information (SUMARI; Joanna
Briggs Institute, Adelaide, Australia). Authors will
be contacted to request full text access where neces-
sary. Study protocols will be requested from authors
of included studies to compare outcomes of interest.
Full-text studies that do not meet the inclusion
criteria will be excluded, and reasons for exclusion
will be provided in an appendix in the final scoping
review report. The results of the search will be
reported in full in the final report and presented in
a PRISMA flow diagram.27
Data extraction
Data will be extracted from papers included in the
review by two independent reviewers (JC andKMM)
using the standardized data extraction tool available
in JBI SUMARI. As a minimum, the following data
will be extracted: study type, author details, journal
of publication and year, participant characteristics,
intervention (type of KDT), each outcome reported,
definition (if used) of outcome, the tool or indicators
used to measure the outcome, validity of tool used,
the time from intervention commencement to mea-
surement of the outcome and the reporting of the
outcome. A draft data extraction tool is provided
(Appendix II). This will be modified and revised as
necessary during the process of extracting data from
each included study. Modifications will be detailed
in the full scoping review report. Any disagreements
that arise between the reviewers (JC and KMM) will
be resolved through discussion or with a third
reviewer (HC). Authors of papers will be contacted
to request missing or additional data where required.
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Data presentation
The extracted data will be presented in a diagram-
matic or tabular form in a manner that is most
relevant to the objective and questions of this scop-
ing review. The tables and charts will report on the
outcomes measured and reported by researchers, the
definitions used to describe these outcomes and the
method of measurement. A narrative summary will
accompany the tabulated and/or charted results and
will describe how the results relate to the reviews
objective and questions. This scoping review is phase
one of a larger project in which the overall aim is to
develop a core outcome set for refractory childhood
epilepsy treated with KD therapy. The study will
identify the outcomes to be measured in clinical
effectiveness trials but will also guide audit or service
evaluation in clinical practice. Parents, health care
professionals, researchers and relevant charities will
be consulted to ensure the final core outcome set
reflects the interests of all and facilitates future
decision making. The study is registered as 1116
on the COMET database of core outcome set studies
(http://www.comet-initiative.org/studies/details/1116).
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Appendix I: Search strategy for PubMed
Diet, Ketogenic [MeSH] OR ketogenic diet [tiab] OR low carbohydrate diet [tiab] OR high-fat [tiab] OR
modified atkins [tiab] OR MCT diet [tiab]
AND
Epilepsy [MeSH] OR seizure[tiab] OR epilep [tiab]
AND
child[MeSH] OR adolescen [MeSH] OR infant [MeSH]OR pediatric [tiab] OR child [tiab] Or infant [tiab]
OR adolescen [tiab] OR teen [tiab]
Limits: 10 years. Search returned 461 records.
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Appendix II: Data extraction form
Author
Journal
Country
Year
Study design
# of subjects
Attrition
Duration
Age range
Primary epilepsy-related diagnosis
Type of ketogenic diet
Outcome
Definition of outcome
Is this stated to be the primary outcome?
Is this stated to be a secondary outcome?
Outcome not stated a priori
Responder (parent or clinician)
Measurement tool
Validity of measurement tool
Time points at which outcome measured
Protocol obtained?
Outcome reported in results?
Outcomes stated in protocol reported in paper?
General comments
SYSTEMATIC REVIEW PROTOCOL J. Carroll et al.
JBI Database of Systematic Reviews and Implementation Reports  2019 THE JOANNA BRIGGS INSTITUTE 7
©2019 Joanna Briggs Institute. Unauthorized reproduction of this article is prohibited.
